Agios PharmaceuticalsAGIO
Recorded

Agios Pharmaceuticals 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration50 minParticipants16

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good morning and welcome to Agios Pharmaceuticals third quarter 2026 conference call. At this time, all participants are in a listen-only mode. There will be a question-and-answer session at the end. Please be advised that this call is being recorded at Agios' request. I would now like to turn the call over to Morgan Sanford, Vice President of Investor Relations at Agios. Thank you. Please go ahead.

Morgan SanfordVP of Investor Relations

Thank you, operator. Good morning, everyone. Thank you for joining us to discuss Agios Pharmaceuticals third quarter 2026 financial results and business highlights. You can access the slides for today's call by going to the Investors section of our website, agios.com. Next slide, please. Please note, we will be making certain forward-looking statements today. Actual events and results could differ materially from those expressed or implied by any forward-looking statements because of various risks, uncertainties, and other factors, including those set forth in our most recent filings with the SEC and any other future filings that we may make with the SEC. On the next slide, we have the agenda for today's call. With me today from Agios are Brian Goff, Chief Executive Officer, Cecilia Jones, Chief Financial Officer, Tsveta Milanova, Chief Commercial Officer, and Dr. Sarah Gheuens, Chief Medical Officer and Head of Research and Development.

Morgan SanfordVP of Investor Relations

Following prepared remarks, we will open the call for questions. With that, I am pleased to turn the call over to Brian.

Brian GoffCEO

Thanks, Morgan. Good morning, everyone, and thank you for joining us. Next slide, please. The third quarter delivered record product revenue for Agios and is a clear demonstration of our commercial execution. We delivered $55.4 million in total net revenue, more than four times the third quarter of last year. U.S. net revenue was $48.7 million, driven by the continued strong U.S. launch of AQVESME in thalassemia. To put that in perspective, in a single quarter, we generated more total revenue than we did in all of 2025. This performance reflects what we are building, a focused rare hematology company with a scalable commercial foundation. Thalassemia is the first launch to leverage that foundation. Sickle cell disease, our largest opportunity, is next, and I will speak to the status of our mitapivat NDA in a moment.

Brian GoffCEO

We ended the quarter with $907 million in cash equivalents, and marketable securities, and are well capitalized to support commercial launches and development of our focused pipeline. Next slide, please. As I mentioned, we have the pieces in place to deliver on the commercial launch of mitapivat in sickle cell disease. Let me take a moment to directly address our recent update on our NDA. As we disclosed last week on October 9, the FDA asked for additional information to evaluate whether a Risk Evaluation and Mitigation Strategy, or REMS, is necessary for mitapivat in sickle cell disease. We responded within 10 days, including approximately nine months of additional safety data from the RISE UP open-label extension period. The FDA classified our response as a major amendment, which procedurally extends the review timeline by three months to February 1, 2027.

Brian GoffCEO

Let me be clear on why we remain confident in a potential approval in sickle cell disease. With this additional follow-up, there continues to be no cases of liver injury in sickle cell disease similar in pattern or severity to those seen in thalassemia. The benefit-risk profile for mitapivat in sickle cell disease is unchanged. The FDA granted this application priority review, recognizing the serious unmet need, and that urgency has not changed. We are in ongoing labeling negotiations with the agency, including elements of a potential REMS, and we are launch-ready. Our commercial, medical, market access, and patient support teams are in place, and we continue to engage closely with the sickle cell community. Our focus is on bringing mitapivat to patients as quickly as possible. Next slide, please. Looking ahead, we are sharpening our focus to drive the next phase of growth. Our strategy is clear. First, maximize the mitapivat franchise, which is now approved in PK deficiency and thalassemia, with sickle cell disease serving as another growth driver from early 2027.

Brian GoffCEO

Second, advance a focused rare hematology pipeline. That includes AG-236 in polycythemia vera, where we plan to initiate a phase II/III program by year-end, and cevidoplenib in immune thrombocytopenia, with a phase III trial planned for the first half of 2028. Importantly, both programs have clinically validated and de-risked mechanisms of action. To support that focus, we have right-sized our operating model. Over the course of 2026, we will have reduced R&D headcount by more than 35% compared with 2025, or more than 100 roles, and we expect associated cost savings to be realized in 2027. We are concentrating our clinical investment on differentiated rare hematology programs, and we are pursuing opportunities to unlock value from non-core assets, including our vorasidenib royalty and AG-181.

Brian GoffCEO

As a result, we will continue to manage operating expenses as we prioritize investment behind our commercial launches and rare hematology pipeline opportunities, and are targeting non-GAAP profitability in 2028. With that, please advance to the next slide, and I'll turn the call over to Cecilia to discuss financials.

Cecilia JonesCFO

Cecilia? Thank you, Brian. Next slide, please.

Cecilia JonesCFO

Turning to our third quarter financial results, total mitapivat net revenue was $55.4 million, including $48.7 million in the U.S. and $6.6 million outside the U.S., compared with $12.9 million in total net revenues in the third quarter of 2025. Cost of sales for the quarter was $2.5 million, compared to $1.7 million in the prior year period. Research and development expense was $73.5 million, compared to $86.8 million in the third quarter of 2025, primarily reflecting reductions in spend associated with mitapivat and tebapivat process development and certain clinical trials. Selling, general, and administrative expense was $56.5 million, compared to $41.3 million in the prior year period, reflecting commercial activities supporting the AQVESME U.S. launch in thalassemia and preparation for a potential U.S. sickle cell disease launch.

Cecilia JonesCFO

Net loss for the third quarter of 2026 was $65 million, compared to a net loss of $103.4 million in the third quarter of 2025. We ended the quarter with $907 million in cash equivalents, and marketable securities, which we believe provides the financial strength to support the AQVESME launch, a potential sickle cell disease launch, and progression of our focused pipeline into non-GAAP profitability in 2028. Turning to our 2026 outlook, full-year operating expenses are expected to remain approximately flat versus 2025, excluding the $25 million upfront payment associated with the cevidoplenib in-licensing, which was recognized in the second quarter, and an approximately $11 million one-time expense associated with the headcount reduction to be recognized in the fourth quarter. Please advance to the next slide, and I'll turn it over to Tsveta to cover commercial highlights.

Tsveta MilanovaChief Commercial Officer

Thank you, Cecilia. Next slide, please. The third quarter was a record quarter for mitapivat, and I'm proud of the execution across the teams, with total mitapivat revenues increasing more than four times the third quarter of last year. In the U.S., net revenue was up 20% sequentially, driven by AQVESME demand across the broad thalassemia population, which I will cover in more detail shortly. Outside the U.S., net revenue increased 74% versus the prior quarter, driven by early access programs in Europe following the European Commission approval for thalassemia in the second quarter. This is an early signal of the global opportunity for mitapivat, which we are pursuing through a capital-efficient model with our partners, Avanzanite in Europe and NewBridge Pharmaceuticals in the GCC. Next slide, please. Now, turning to U.S. demand for AQVESME in thalassemia.

Tsveta MilanovaChief Commercial Officer

As a reminder, an Agios Start Form is submitted with an AQVESME prescription when the patient and physician opt into our support program. In the third quarter, we added 177 prescriptions from REMS-certified physicians with completed start forms, bringing the total to 619 since launch, which is roughly 15% of our target launch population of about 4,000 patients, only three quarters into launch. This is the last quarter we'll report this metric, so for a complete picture, another 48 prescriptions had start forms in process at quarter end. We communicated previously that first quarter start forms benefited from pent-up demand built during the extended thalassemia FDA review periods. We are now seeing the steady broadening we planned for into community practices and non-transfusion-dependent patients, where treatment decisions take more time. On persistency, approximately 75% of patients remain on therapy at about six months.

Tsveta MilanovaChief Commercial Officer

This is exactly the foundation we want, a durable base of patients that build over time. Looking ahead, we are focused on two things. On persistency, making sure prescribers know the long-term clinical data we have generated so patients stay on treatment long enough to benefit. On demand, we are expanding our reach in the community setting, deepening adoption in transfusion-dependent patients, and driving uptake in non-transfusion-dependent patients. We are also activating patients themselves through the first direct-to-consumer campaign. Next slide, please. In August, we launched LEVEL UP with AQVESME, our first direct-to-consumer campaign, a targeted omnichannel effort. This month, we are expanding with multilingual assets to reach the diverse thalassemia community. Earlier results are encouraging, and after the launch, we saw a 65% increase in engagement on our patient website. Please move to the next slide. Feedback from treating physicians continues to reinforce the value of AQVESME in thalassemia.

Tsveta MilanovaChief Commercial Officer

Recent market research shows broad enthusiasm across both transfusion-dependent and non-transfusion-dependent segments. We are encouraged by the momentum three quarters into launch. As the first medicine approved for the broad thalassemia population, AQVESME is well-positioned for continued growth, and I'm confident in our team's ability to deliver. Next slide, please. Turning to sickle cell disease. As Brian said, we are launch-ready and will use the additional time to prepare even further ahead of our February 1st PDUFA goal date. There are approximately 75,000 diagnosed patients aged 16 and older in the U.S. Our initial launch focus is approximately 25,000 patients who are actively treated or in need of therapy, and we will prioritize these patients with hemolytic profile, defined by low or declining hemoglobin. This focused approach is designed to drive speed of adoption. This launch builds on the commercial foundation we established for thalassemia.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day